Navigation Links
IsoRay Announces A New International Distributor For Greece
Date:5/21/2013

interest, we remain committed to our strategic national and international marketing objectives and believe this will contribute to our long term success."

The Company is actively bringing new brachytherapy applications to market in support of leading physicians throughout the world needing new solutions. The Company's continued investment in research and development focusing on Cs-131 efficacy for various cancers located throughout the body is expected to have a direct impact on its overall revenue growth with an expanding array of non-prostate cancer treatments. In addition, the increase in the size, quality and reorganization of IsoRay's sales organization in the US market has created the means to contact more facilities than ever before with the Company's new and novel treatment alternatives.

About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which is expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter@Isoray.

Contact:
Worldwide Financial
(954) 360-9998
Info@wwfinancial.com

Safe Harbor Statement

Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, future demand for IsoRay's existing and planned products, whether regulatory approvals and licenses will be obtained or maintained in foreign countries, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether IsoRay will be able to generate sales in the U.S. and internationally, whether additional studies will be published with favorable outcomes from treatment with Cesium-131, whethe
'/>"/>

SOURCE IsoRay, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- Una presentazione speciale durante la settimana della prevenzione ... di MERG valutare i successi ottenuti grazie all,adozione ... popolazioni di pazienti affetti dalla patologia. ... Fass , MD della Case Western Reserve University, ha ... alla terapia Stretta. Un panel di esperti ha quindi ...
(Date:5/27/2015)... -- Biosensors International Group, Ltd. ("Biosensors " or the ... developer, manufacturer and marketer of innovative medical devices, today ... FY15") and fiscal full year ended 31 March 2015 ... , Q4 FY15: , Total revenue of ... Fiscal Year 2014 ("Q4 FY14") due to licensing revenue ...
(Date:5/27/2015)... , May 27, 2015  PDL BioPharma, Inc. ... John P. McLaughlin , the company,s president and chief ... Healthcare Conference next week in New York City.  The ... June 3, 2015 at 11:30 a.m. EDT. ... the presentation, go to the Company,s website at ...
Breaking Medicine Technology:Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 2Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 3Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 4Biosensors Reports Financial Results for Fiscal Year 2015 2Biosensors Reports Financial Results for Fiscal Year 2015 3Biosensors Reports Financial Results for Fiscal Year 2015 4Biosensors Reports Financial Results for Fiscal Year 2015 5Biosensors Reports Financial Results for Fiscal Year 2015 6Biosensors Reports Financial Results for Fiscal Year 2015 7PDL BioPharma to Present at Jefferies 2015 Global Healthcare Conference 2
... TRIANGLE PARK, N.C., Jan. 6, 2011 CeNeRx BioPharma, Inc., today ... new formulation of TriRima ™, the company,s novel antidepressant in ... it will be presenting at Biotech Showcase™ ... 11:00 AM PST. TriRima is a member ...
... Pharmasset, Inc. (Nasdaq: VRUS ), announced today positive ... HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase ... dual nucleotide study.   Pipeline Update and ... PSI-7977 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a ...
Cached Medicine Technology:CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression 2CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression 3Pharmasset Reports Positive Results from its HCV Clinical Programs 2Pharmasset Reports Positive Results from its HCV Clinical Programs 3Pharmasset Reports Positive Results from its HCV Clinical Programs 4Pharmasset Reports Positive Results from its HCV Clinical Programs 5Pharmasset Reports Positive Results from its HCV Clinical Programs 6
(Date:5/27/2015)... SAN DIEGO, May 27, 2015 ... the first healthcare provider along the Gulf Coast ... management (CCM). In partnership with MD Revolution, a ... a new program that enables healthcare providers to ... reimbursements. This new, user-friendly program is designed to ...
(Date:5/27/2015)... May 27, 2015 CompanionDx ... and somatic genomic analysis in personalized cancer therapy: Non-small ... the American Society of Clinical Oncology (ASCO) as part ... in Chicago. , The molecular and clinical data used ... Atlas (TCGA) database. The study reports improved patient outcomes ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 On June ... advertising agency, will partner with LifeSource to host Donate ... will take place in a LifeSource donor coach outside ... to 4:00 p.m. , Demand for whole blood units ... Illinois, during the summer months. LifeSource requires approximately 1,000 ...
(Date:5/27/2015)... Dallas, Texas (PRWEB) May 27, 2015 ... on the current state of the Omega-3 industry. ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ... Products, Gc Rieber Oils, Camanchaca Fishing Company, Seadragon ...
(Date:5/27/2015)... 2015 SonarMD, LLC, recently ... a first-of-its kind, cloud-based algorithmic process for ... chronic gastrointestinal disease. , Developed by noted ... allows physicians to monitor their patients’ health ... of electronic health assessment surveys. Using nationally ...
Breaking Medicine News(10 mins):Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... West Indies cricket captain Brian Lara has thrown a punch ... opening of a cancer center named after him. ... and management of the Brian Lara Cancer Center for their ... "missed" the (West Indies) the Cricket Board. ,His ...
... people with celiac disease are waiting an average of 13 ... gut disorder caused by gluten intolerance, and can lead to ... is a protein group found in wheat and other flours ... the carbon dioxide (CO2) produced by the yeast and expands ...
... all the wrong reasons. ,Civic authorities ... who use the Hudson River of the potential health problems ... the river after a main broke Friday afternoon. ... in contact with the sewage and ingesting bacteria that could ...
... the seizure drug valporate, which is marketed by Abbott ... their risk of having an infant with mental ... annual meeting of the American Academy of Neurology in ... Meador, professor of neurology at the University of Florida, ...
... underwent a simultaneous liver and kidney transplant at a ... claimed as the first such in the world. ... as primary Hyperoxaluria, in which the liver lacks an ... bones, heart and pancreas. Patients suffering from the disease ...
... who are on estrogen therapy before the age of 65. ... risk of Alzheimers disease or dementia. ,The study showed ... the age of 65 cut their risk of dementia by 50%, ... the age of 65. ,This study was part ...
Cached Medicine News:Health News:Gluten Intolerance Cases Diagnosed Late in UK 2Health News:Sewage Flows into Hudson River in a Torrent 2Health News:Sewage Flows into Hudson River in a Torrent 3Health News:NRI Boy Underwent a Rare Dual Transplant Surgery 2
Sample throughput of up to 80 tests per hour (4 modules). Low maintenance requirements. Continuous random access. 25 - 100 channels on board. 1008 tests or 6 hours of walkaway operation....
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca...
Elisa Plate Reader...
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Medicine Products: